Upcoming Sessions
| DATE | TITLE | PRESENTER | REGISTER |
|---|---|---|---|
|
Wed, Apr 1, 2026
10:00 – 11:00 PM UTC
|
Facing Fear & Pain in Amyloidosis: How to Take Back Control and Shorten the Storm | Cath Jayasuriya | Click To Register |
|
Thu, Apr 2, 2026
10:00 – 11:00 PM UTC
|
You Are Not Behind. You Are in Different Territory. | Francesco Clark | Click To Register |
|
Wed, Apr 8, 2026
10:00 – 11:00 PM UTC
|
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next | Heather Landau | Click To Register |
|
Thu, Apr 9, 2026
10:00 – 11:00 PM UTC
|
Rare and Remarkable: Turning Challenges into Purpose | Michele Wright | Click To Register |
Wed, Apr 1, 2026 · 10:00 – 11:00 PM UTC
Facing Fear & Pain in Amyloidosis: How to Take Back Control and Shorten the Storm
Cath Jayasuriya
Click To Register
Thu, Apr 2, 2026 · 10:00 – 11:00 PM UTC
You Are Not Behind. You Are in Different Territory.
Francesco Clark
Click To Register
Wed, Apr 8, 2026 · 10:00 – 11:00 PM UTC
CAR-T Therapy for AL Amyloidosis: What’s New, What’s Real, and What’s Next
Heather Landau
Click To Register
Thu, Apr 9, 2026 · 10:00 – 11:00 PM UTC
Rare and Remarkable: Turning Challenges into Purpose
Michele Wright
Click To Register
Cardiomyopathy
Aug 27, 2023
The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…
Jan 29, 2023
What is this plain language summary about?
This summary presents the results from an ongoing, long-term extension studyexternal link, opens in a new tab that…
Dec 19, 2021
Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of…
Apr 30, 2020
Cardiac amyloidosis is a heterogeneous group of diseases characterized by extracellular deposition of amyloid fibrils in many different organs finally resulting in…
Jun 05, 2019
For the first time, we report of a Swedish family of five individuals with a TTR Glu54Leu (p. Glu74Leu) mutation in the transthyretin gene. This mutation has been…
Aug 05, 2016
The heart and the kidneys are the most commonly involved organs in systemic amyloidosis. Cardiac involvement is associated with an increased morbidity, treatment…
Oct 13, 2014
Amyloid cardiomyopathy should be suspected in any patient who presents with heart failure and preserved ejection fraction. In patients with echocardiographic…
Introduction:
Cardiac amyloidosis is the most common cause of infiltrative cardiomyopathy and is associated with a poor prognosis. Transthyretin cardiac amyloidosis…
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL(R) (tafamidis meglumine) and VYNDAMAX(tm) (tafamidis) for…
Ronglih Liao is Co-Director of the Stanford Amyloid Center and Professor of Medicine at Stanford University School of Medicine. She is also a visiting Professor of…